NTLA
Neutral signalScored 2026-08-27 Drivers: fundamentals. Insiders: neutral. Moteurs : fondamentaux. Initiés : neutre.
Research, not advice.
À propos
Intellia Therapeutics, Inc.
- Nom
- Intellia Therapeutics, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $1.5B
- Employés
- 377
- PDG
- John Leonard
- Site web
- https://www.intelliatx.com
- Marché
- BEAMCRBUCRSPEDITMGTXMGX
Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developing various other liver-focused therapies for conditions such as hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo (processed outside the body) pipeline features NTLA-5001, a candidate for acute myeloid leukemia. The company is also progressing proprietary programs focused on creating engineered cell therapies to address diverse oncological and autoimmune disorders. At the core of Intellia's technology is the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has established multiple licensing and collaboration agreements. These include a partnership with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for treating sickle cell disease, and a co-development agreement with Regeneron Pharmaceuticals, Inc. for potential products against hemophilia A and B. The company also collaborates with Ospedale San Raffaele and holds a strategic alliance with SparingVision SAS to develop novel genomic medicines for ocular diseases, leveraging CRISPR/Cas9 technology. The company, initially known as AZRN, Inc., was founded in 2014 and operates from its headquarters in Cambridge, Massachusetts.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 22 675 titres (~286 819,00 $ US)
- Insiders
- LEONARD JOHN M
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$309,989
Avg sell (VWAP, 90d window) $12.63 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$286,819 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-08-21
- Last synced
-
2026-08-27 10:00:12
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-02 | Dube Michael P | Sell · S | 1,864 | $12.43 | $23,170 | Form 4 |
| 2026-08-21 | LEONARD JOHN M | Sell · S · 10b5-1 | 2,785 | $13.00 | $36,205 | Form 4 |
| 2026-08-20 | LEONARD JOHN M | Sell · S · 10b5-1 | 19,890 | $12.60 | $250,614 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2022-02-28 | Donald Sternoff Beyer | Sale (Full) | $15,001 - $50,000 |
| 2021-10-29 | Donald Sternoff Beyer | Sale (Full) | $1,001 - $15,000 |
| 2021-09-20 | Donald Sternoff Beyer | Sale (Full) | $1,001 - $15,000 |
| 2021-07-21 | Donald Sternoff Beyer | Sale (Full) | $1,001 - $15,000 |
| 2021-01-15 | Donald Sternoff Beyer | Sale (Full) | $1,001 - $15,000 |
| 2020-11-18 | Donald Sternoff Beyer | Purchase | $1,001 - $15,000 |
| 2020-08-26 | Donald Sternoff Beyer | Sale (Full) | $1,001 - $15,000 |
| 2020-07-10 | Donald Sternoff Beyer | Purchase | $1,001 - $15,000 |
| 2020-01-14 | Donald Sternoff Beyer | Purchase | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-08-27 Drivers: fundamentals. Insiders: neutral. Moteurs : fondamentaux. Initiés : neutre.
NTLA combines a weak catalyst score (20) with deteriorating fundamentals (trend score: 25), reflecting a pre-revenue biotech burning cash with no near-term path to profitability.
The first sentence of the analysis written for NTLA on 2026-08-27 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. – Insider: neutral. All sales (≈ $287K) were pre-planned Rule 10b5-1 trades, excluded from the score. No open-market buys or discretionary sales. – Initiés : neutre. Toutes les ventes (≈ $287K) sont sous plan 10b5-1 préétabli, exclues du score. Aucun achat ni vente discrétionnaire.
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. Current ratio 5.08 · operating margin -652% — readings disagree
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 76.5% | 82.2% | 75.3% | 85.5% | 79.2% | |
| Ebit Margin | -609.9% | -896.8% | -1326.5% | -909.8% | -810.5% | |
| Ebitda Margin | -586.3% | -879.0% | -1301.8% | -895.3% | -789.6% | |
| Operating Profit Margin | -651.7% | -923.1% | -1420.5% | -879.0% | -810.4% | |
| Pretax Profit Margin | -609.9% | -896.8% | -1326.5% | -909.8% | -810.5% | |
| Continuous Operations Profit Margin | -609.9% | -896.8% | -1326.5% | -909.8% | -810.5% | |
| Net Profit Margin | -609.9% | -896.8% | -1326.5% | -909.8% | -810.5% | |
| Bottom Line Profit Margin | -609.9% | -896.8% | -1326.5% | -909.8% | -810.5% | |
| Current Ratio | 5.080 | 5.772 | 8.665 | 9.615 | 6.114 | |
| Quick Ratio | 5.080 | 5.772 | 8.665 | 9.615 | 6.114 | |
| Solvency Ratio | -2.324 | -1.594 | -1.883 | -1.640 | -1.027 | |
| Cash Ratio | 1.497 | 1.707 | 1.968 | 4.137 | 0.981 | |
| Price To Earnings Ratio | -2.360 | -2.221 | -5.625 | -5.664 | -31.280 | |
| Price To Earnings Growth Ratio | 0.086 | 0.708 | 0.468 | -0.090 | -0.544 | |
| Forward Price To Earnings Growth Ratio | 0.086 | 0.708 | 0.468 | -0.090 | -0.544 | |
| Price To Earnings Diluted Ratio | -2.360 | -2.221 | -5.625 | -5.664 | -31.280 | |
| Price To Earnings Diluted Growth Ratio | 0.086 | 0.708 | 0.468 | -0.090 | -0.544 | |
| Price To Book Ratio | 1.451 | 1.322 | 2.577 | 2.174 | 8.058 | |
| Price To Sales Ratio | 14.398 | 19.914 | 74.613 | 51.525 | 253.608 | |
| Price To Free Cash Flow Ratio | -2.747 | -3.250 | -6.633 | -6.857 | -35.252 | |
| Price To Operating Cash Flow Ratio | -2.793 | -3.304 | -6.868 | -8.058 | -37.251 | |
| Debt To Assets Ratio | 0.111 | 0.176 | 0.089 | 0.086 | 0.057 | |
| Debt To Equity Ratio | 0.139 | 0.241 | 0.110 | 0.106 | 0.071 | |
| Debt To Capital Ratio | 0.122 | 0.194 | 0.099 | 0.096 | 0.066 | |
| Long Term Debt To Capital Ratio | 0.091 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.254 | 1.366 | 1.239 | 1.230 | 1.244 | |
| Working Capital Turnover Ratio | 0.142 | 0.082 | 0.037 | 0.060 | 0.055 | |
| Operating Cash Flow Ratio | -3.358 | -3.147 | -3.421 | -2.634 | -1.788 | |
| Operating Cash Flow Sales Ratio | -5.156 | -6.028 | -10.864 | -6.394 | -6.808 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.017 | 1.017 | 1.035 | 1.175 | 1.057 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -3.738 | -1.660 | -3.417 | -2.550 | -3.040 | |
| Capital Expenditure Coverage Ratio | -60.381 | -60.381 | -28.179 | -5.708 | -17.641 | |
| Dividend Paid And Capex Coverage Ratio | -60.381 | -60.381 | -28.179 | -5.708 | -17.641 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -2.299 | -2.307 | -5.496 | -4.914 | -31.928 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 76.5% | ▼-5.8% | ▼-3.2% |
| Ebit Margin | -609.8% | ▲286.9% | ▲300.8% |
| Ebitda Margin | -586.3% | ▲292.7% | ▲304.1% |
| Operating Profit Margin | -651.7% | ▲271.4% | ▲285.3% |
| Pretax Profit Margin | -609.8% | ▲286.9% | ▲300.8% |
| Continuous Operations Profit Margin | -609.8% | ▲286.9% | ▲300.8% |
| Net Profit Margin | -609.8% | ▲286.9% | ▲300.8% |
| Bottom Line Profit Margin | -609.8% | ▲286.9% | ▲300.8% |
| Current Ratio | 5.080 | ▼-0.693 | ▼-1.969 |
| Quick Ratio | 5.080 | ▼-0.693 | ▼-1.969 |
| Solvency Ratio | -2.324 | ▼-0.729 | ▼-0.630 |
| Cash Ratio | 1.496 | ▼-0.210 | ▼-0.561 |
| Price To Earnings Ratio | -2.360 | ▼-0.139 | ▲7.071 |
| Price To Earnings Growth Ratio | 0.086 | ▼-0.622 | ▼-0.040 |
| Forward Price To Earnings Growth Ratio | 0.086 | ▼-0.622 | ▼-0.040 |
| Price To Earnings Diluted Ratio | -2.360 | ▼-0.139 | ▲7.071 |
| Price To Earnings Diluted Growth Ratio | 0.086 | ▼-0.622 | ▼-0.040 |
| Price To Book Ratio | 1.451 | ▲0.129 | ▼-1.665 |
| Price To Sales Ratio | 14.398 | ▼-5.517 | ▼-68.414 |
| Price To Free Cash Flow Ratio | -2.747 | ▲0.503 | ▲8.200 |
| Price To Operating Cash Flow Ratio | -2.793 | ▲0.511 | ▲8.862 |
| Debt To Assets Ratio | 0.111 | ▼-0.066 | ▲0.007 |
| Debt To Equity Ratio | 0.139 | ▼-0.102 | ▲0.006 |
| Debt To Capital Ratio | 0.122 | ▼-0.072 | ▲0.007 |
| Long Term Debt To Capital Ratio | 0.091 | ▲0.091 | ▲0.072 |
| Financial Leverage Ratio | 1.254 | ▼-0.112 | ▼-0.012 |
| Working Capital Turnover Ratio | 0.142 | ▲0.060 | ▲0.067 |
| Operating Cash Flow Ratio | -3.358 | ▼-0.211 | ▼-0.489 |
| Operating Cash Flow Sales Ratio | -5.155 | ▲0.872 | ▲1.895 |
| Free Cash Flow Operating Cash Flow Ratio | 1.017 | 0.000 | ▼-0.043 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -3.738 | ▼-2.078 | ▼-0.857 |
| Capital Expenditure Coverage Ratio | -60.381 | 0.000 | ▼-25.923 |
| Dividend Paid And Capex Coverage Ratio | -60.381 | 0.000 | ▼-25.923 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -2.299 | ▲0.008 | ▲7.090 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $974.3M | $1.15B | $2.71B | $2.69B | $8.38B | |
| Enterprise value | $912.2M | $1.17B | $2.60B | $2.29B | $8.33B | |
| EV / Sales | 13.48x | 20.28x | 71.54x | 43.99x | 252.11x | |
| EV / Op. cash flow | -2.62x | -3.36x | -6.58x | -6.88x | -37.03x | |
| EV / Free cash flow | -2.57x | -3.31x | -6.36x | -5.85x | -35.05x | |
| EV / EBITDA | -2.30x | -2.31x | -5.50x | -4.91x | -31.93x | |
| Net debt / EBITDA | 0.16x | -0.04x | 0.24x | 0.84x | 0.19x | |
| Current ratio | 5.08x | 5.77x | 8.66x | 9.62x | 6.11x | |
| Income quality | 0.67x | 0.67x | 0.82x | 0.70x | 0.84x | |
| Graham net-net | $3 | $3 | $8 | $12 | $7 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Working capital | $423.8M | $529.0M | $883.1M | $1.09B | $643.5M | |
| Invested capital | $547.5M | $775.7M | $1.03B | $1.25B | $743.6M | |
| Return on assets | -49.0% | -43.6% | -37.0% | -31.2% | -20.7% | |
| Operating ROA | -43.4% | -42.9% | -36.5% | -32.6% | -27.2% | |
| Return on tangible assets | -49.0% | -43.6% | -37.0% | -31.2% | -20.7% | |
| Return on equity | -61.5% | -59.5% | -45.8% | -38.4% | -25.8% | |
| Return on invested capital | -57.7% | -48.6% | -42.8% | -32.5% | -22.7% | |
| Return on capital employed | -59.7% | -49.5% | -43.5% | -32.9% | -22.9% | |
| Earnings yield | -42.4% | -45.0% | -17.8% | -17.7% | -3.2% | |
| Free cash flow yield | -36.4% | -30.8% | -15.1% | -14.6% | -2.8% | |
| Capex / Op. cash flow | -1.7% | -1.7% | -3.5% | -17.5% | -5.7% | |
| Capex / Depreciation | 56.2% | 56.2% | 155.8% | 771.1% | 185.1% | |
| Capex / Sales | 8.5% | 10.0% | 38.6% | 112.0% | 38.6% | |
| SG&A / Sales | 177.0% | 217.4% | 321.1% | 173.3% | 215.1% | |
| R&D / Sales | 574.6% | 805.7% | 1199.4% | 805.8% | 695.3% | |
| Stock comp / Sales | 228.0% | 266.6% | 369.5% | 175.4% | 142.2% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 51d | 54d | 367d | 26d | 22d | |
| Days payables outstanding | 464d | 518d | 303d | 248d | 511d | |
| Operating cycle | 51d | 54d | 367d | 26d | 22d | |
| Cash conversion cycle | -413d | -464d | 64d | -222d | -489d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-08-24 4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains CRSP, NTLA, BEAM and EDIT offer distinct gene-editing opportunities, spanning commercial validation, late-stage catalysts and promising early-stage programs.
- 2026-08-07 Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on August 1, 2026, it awarded inducement grants to eight new employees under Intellia''s 2024 Inducement Plan, as amended, as a material inducement to employment.
- 2026-08-07 NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron Revenues Intellia''s Q2 loss matches estimates, but revenues fall 46.2% as lower Regeneron collaboration revenues weigh on results.
- 2026-08-07 Intellia Therapeutics Q2 Earnings Call Highlights Intellia Therapeutics NASDAQ: NTLA said it advanced its lead gene-editing programs during the second quarter, highlighting positive Phase III results for lonvo-z in hereditary angioedema and the resumption of enrollment in Phase III studies of nex-z for transthyretin amyloidosis.
- 2026-08-06 Intellia Therapeutics, Inc. (NTLA) Q2 2026 Earnings Call Transcript Intellia Therapeutics, Inc. (NTLA) Q2 2026 Earnings Call Transcript
- 2026-08-06 Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $0.8 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.99 per share a year ago.
- 2026-08-06 Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates CAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today reported business updates and financial results for the second quarter ended June 30, 2026.
- 2026-08-03 Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Recommendation of “Hold” by Brokerages Shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA - Get Free Report) have received an average recommendation of "Hold" from the twenty-three research firms that are currently covering the company, Marketbeat reports. Four investment analysts have rated the stock with a sell rating, nine have given a hold rating, nine have issued a buy rating and one
- 2026-07-30 Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates CAMBRIDGE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that the company will host a conference call on August 6, 2026, at 8 a.m. ET to discuss its second quarter 2026 financial results and business updates.
- 2026-07-21 Amova Asset Management Americas Inc. Reduces Stake in Intellia Therapeutics, Inc. $NTLA Amova Asset Management Americas Inc. cut its position in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) by 10.0% in the undefined quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,973,061 shares of the company''s stock after selling 219,400 shares during the quarter. Amova Asset Management